

EV0049

Intramuscular ketamine in depression, suicidal thoughts and anxiety: A report on two cases

M. Cigognini*, R. Moreno

Institute of Psychiatry, GRUDA, São Paulo, Brazil

* Corresponding author.

Introduction Several studies have shown that ketamine, an antagonist of NMDA receptors, represents a promising alternative in the treatment of depression. The therapeutic use of ketamine, commonly used at a dose of 0.5 mg/kg, and in a single application IV has been short and requires monitoring in a hospital setting. IM use has been shown to be effective in treating depression and suicide risk, and have low side effect profile.

Methods Two patients diagnosed with bipolar depression and suicide risk were submitted to ketamine IM application (0.75 mg/kg), receiving one application of ketamine IM every two days, totaling 4 applications. Patients were under medical monitoring for 2 hours after injection verifying vital signs and potential side effects. Responses were measured using BDI, BAI and BSI.

Aim To evaluate response of ketamine IM injections on depressive, suicidal and anxious symptoms.

Summary Case 1: female, 20 years old, single with three recent suicide attempts, symptomatic for two months. Started lithium 450 mg daily. Side effects of ketamine were nausea, drowsiness and paresthesia. Case 2: female, 24 years old, single with symptoms lasting for six years. Started aripiprazole 5–10 mg and 25 mg lamotrigine concomitantly. Side effects of dry mouth, dizziness and dissociation.

Conclusions The use of ketamine IM showed reduction of 75.5%–83.3%–85.7% (case 1) and 71.4%–77.2%–60.8% (case 2) in BDI, BAI and BSI, respectively as well as safety and tolerability in use.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2017.01.378>

EV0050

Reversible cognitive impairment associated with a high free fraction but subtherapeutic total blood level of valproic acid due to hypoalbuminemia in a bipolar patient

G. Dautzenberg^{1,*}, M. Nederlof², E. Heerdink², A. Beekman³

¹ Altrecht GGZ, Old Age Psychiatry, Utrecht, The Netherlands

² Utrecht University, Utrecht Institute of Pharmaceutical Sciences, Utrecht, The Netherlands

³ VU University Medical Center, Department of Psychiatry, Amsterdam, The Netherlands

* Corresponding author.

Valproic acid (VPA) is widely used in the treatment of epilepsy and bipolar disorder. It is largely bound to serum proteins (80–95%) in particular albumin, with a saturable binding capacity. Under conditions of hypoalbuminemia, protein binding of VPA will decrease and its pharmacologically-active free fraction will rise, even to toxic levels while measuring subtherapeutic VPA total blood levels [1].

We present an elderly bipolar patient with (sub)clinical total levels of VPA and a high free fraction of VPA due to hypoalbuminemia (14–24 g/L) leading to severe reversible cognitive impairment.

VPA and the free fraction in particular, was the most likely cause of the cognitive impairment [2]. There was a time-correlation with increasing blood levels of total VPA (68 mg/L, reference 80–120 mg/L [3]), notably the free fraction (37.5 mg/L, reference 5–15 mg/L), and the intoxication.

For therapeutic drug monitoring in laboratories, generally, total VPA concentrations (free + protein-bound) are measured instead of

free fractions, due to technical difficulties, a lack of established reference ranges [4] and (inter)national guidelines [5,6] not requiring it. This presentation and literature points out that it is clinically relevant to measure the free fraction [7,8], especially in patients with hypoalbuminemia [9–11] to prevent unnecessary side effects and toxicity.

We recommend measuring albumin during VPA use; particularly in patients with nephrotic syndrome, liver disease [12] or older adults [13–15]. Hypoalbuminemia demands a free fraction measurement.

Disclosure of interest The authors have not supplied their declaration of competing interest.

References

- [1] Hermida 2005.
- [2] Naranjo 1981.
- [3] TDM <http://tdm-monografie.org/monografie/valproinezuur>.
- [4] Dasgupa 2002.
- [5] NICE or NvVP bipolar disorder guidelines.
- [6] Dols 2016.
- [7] Levy 1980.
- [8] Jager Roman 1982.
- [9] Haroldson 2000.
- [10] Maat de 2011.
- [11] Jansen 2012.
- [12] Dasgupa 2007.
- [13] Rej 2012.
- [14] Beyenburg 2007.
- [15] Kodama 2002.

<http://dx.doi.org/10.1016/j.eurpsy.2017.01.379>

EV0051

Care pathways for patients with bipolar disorders at Psychiatry Clinic Affektiva, Gothenburg: Identifying and solving issues for a more efficient and safe care

M. Dellepiane*, C. Boldt-Christmas, G. Jungstrand, P. Asplund, R. Ahmed, T. Nordin

Sahlgremska University Hospital, Psychiatry, Gothenburg, Sweden

* Corresponding author.

Introduction The Psychiatry Clinic Affektiva has developed a care pathway for patients with bipolar disorder (BD). It consists of one outpatient clinic and two inpatient wards. Clinical observations suggest that patients with BD benefit from treatment in a dedicated unit with tailored care programs and that better outcomes are achieved in terms of reduced average length of stay and safer transitions to outpatient care for this group.

Aims The aim is to improve the care of bipolar patients by increasing bed-availability and overall continuity in the care pathway and monitoring core aspects in the management of outpatients in order to reduce admissions and to facilitate standardized treatment and collaboration between in- and outpatients unit.

Method We developed a structure to monitor and measure specific outcomes such as readmission within 28 days, relapse within 12 months and the use of lithium in this group. We also developed a standardized care protocol in order to improve the safety and the equality.

Results At this stage our preliminary results from our efforts are promising but further monitoring is needed to confirm our hypothesis. More data will be collected during 2017.

Conclusions Affektiva Psychiatry Clinic has developed a model for continuously monitoring several essential aspects in the care of patients with BD and providing a specific care program.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2017.01.380>